Search

Your search keyword '"Plitt, Tamar"' showing total 16 results
Start Over Author "Plitt, Tamar"
16 results on '"Plitt, Tamar"'

1. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19

Author

Britton, Graham J., Chen-Liaw, Alice, Cossarini, Francesca, Livanos, Alexandra E., Spindler, Matthew P., Plitt, Tamar, Eggers, Joseph, Mogno, Ilaria, Gonzalez-Reiche, Ana S., Siu, Sophia, Tankelevich, Michael, Grinspan, Lauren Tal, Dixon, Rebekah E., Jha, Divya, van de Guchte, Adriana, Khan, Zenab, Martinez-Delgado, Gustavo, Amanat, Fatima, Hoagland, Daisy A., tenOever, Benjamin R., Dubinsky, Marla C., Merad, Miriam, van Bakel, Harm, Krammer, Florian, Bongers, Gerold, Mehandru, Saurabh, and Faith, Jeremiah J.

Published
2021
Full Text
View/download PDF

3. The New Era of Cancer Immunotherapy

Author

Khalil, Danny N., primary, Budhu, Sadna, additional, Gasmi, Billel, additional, Zappasodi, Roberta, additional, Hirschhorn-Cymerman, Daniel, additional, Plitt, Tamar, additional, De Henau, Olivier, additional, Zamarin, Dmitriy, additional, Holmgaard, Rikke B., additional, Murphy, Judith T., additional, Wolchok, Jedd D., additional, and Merghoub, Taha, additional

Published
2015
Full Text
View/download PDF

4. Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms

Author

Livanos, Alexandra E., primary, Jha, Divya, additional, Cossarini, Francesca, additional, Gonzalez-Reiche, Ana S., additional, Tokuyama, Minami, additional, Aydillo, Teresa, additional, Parigi, Tommaso L., additional, Ladinsky, Mark S., additional, Ramos, Irene, additional, Dunleavy, Katie, additional, Lee, Brian, additional, Dixon, Rebekah E., additional, Chen, Steven T., additional, Martinez-Delgado, Gustavo, additional, Nagula, Satish, additional, Bruce, Emily A., additional, Ko, Huaibin M., additional, Glicksberg, Benjamin S., additional, Nadkarni, Girish, additional, Pujadas, Elisabet, additional, Reidy, Jason, additional, Naymagon, Steven, additional, Grinspan, Ari, additional, Ahmad, Jawad, additional, Tankelevich, Michael, additional, Bram, Yaron, additional, Gordon, Ronald, additional, Sharma, Keshav, additional, Houldsworth, Jane, additional, Britton, Graham J., additional, Chen-Liaw, Alice, additional, Spindler, Matthew P., additional, Plitt, Tamar, additional, Wang, Pei, additional, Cerutti, Andrea, additional, Faith, Jeremiah J., additional, Colombel, Jean-Frederic, additional, Kenigsberg, Ephraim, additional, Argmann, Carmen, additional, Merad, Miriam, additional, Gnjatic, Sacha, additional, Harpaz, Noam, additional, Danese, Silvio, additional, Cordon-Cardo, Carlos, additional, Rahman, Adeeb, additional, Schwartz, Robert E., additional, Kumta, Nikhil A., additional, Aghemo, Alessio, additional, Bjorkman, Pamela J., additional, Petralia, Francesca, additional, van Bakel, Harm, additional, Garcia-Sastre, Adolfo, additional, and Mehandru, Saurabh, additional

Published
2021
Full Text
View/download PDF

5. Gastrointestinal involvement attenuates COVID-19 severity and mortality

Author

Livanos, Alexandra E., primary, Jha, Divya, additional, Cossarini, Francesca, additional, Gonzalez-Reiche, Ana S., additional, Tokuyama, Minami, additional, Aydillo, Teresa, additional, Parigi, Tommaso L., additional, Ramos, Irene, additional, Dunleavy, Katie, additional, Lee, Brian, additional, Dixon, Rebekah, additional, Chen, Steven T., additional, Martinez-Delgado, Gustavo, additional, Nagula, Satish, additional, Ko, Huaibin M., additional, Reidy, Jason, additional, Naymagon, Steven, additional, Grinspan, Ari, additional, Ahmad, Jawad, additional, Tankelevich, Michael, additional, Gordon, Ronald, additional, Sharma, Keshav, additional, Britton, Graham J., additional, Chen-Liaw, Alice, additional, Spindler, Matthew P., additional, Plitt, Tamar, additional, Wang, Pei, additional, Cerutti, Andrea, additional, Faith, Jeremiah J., additional, Colombel, Jean-Frederic, additional, Kenigsberg, Ephraim, additional, Argmann, Carmen, additional, Merad, Miriam, additional, Gnjatic, Sacha, additional, Harpaz, Noam, additional, Danese, Silvio, additional, Rahman, Adeeb, additional, Kumta, Nikhil A., additional, Aghemo, Alessio, additional, Petralia, Francesca, additional, Bakel, Harm van, additional, Garcia-Sastre, Adolfo, additional, and Mehandru, Saurabh, additional

Published
2020
Full Text
View/download PDF

6. SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19

Author

Britton, Graham J., primary, Chen-Liaw, Alice, additional, Cossarini, Francesca, additional, Livanos, Alexandra E., additional, Spindler, Matthew P., additional, Plitt, Tamar, additional, Eggers, Joseph, additional, Mogno, Ilaria, additional, Gonzalez-Reiche, Ana S., additional, Siu, Sophia, additional, Tankelevich, Michael, additional, Grinspan, Lauren Tal, additional, Dixon, Rebekah E., additional, Jha, Divya, additional, Martinez-Delgado, Gustavo, additional, Amanat, Fatima, additional, Hoagland, Daisy A., additional, tenOever, Benjamin R., additional, Dubinsky, Marla C., additional, Merad, Miriam, additional, Bakel, Harm van, additional, Krammer, Florian, additional, Bongers, Gerold, additional, Mehandru, Saurabh, additional, and Faith, Jeremiah J., additional

Published
2020
Full Text
View/download PDF

7. Immunology of COVID-19: Current State of the Science

Author

Vabret, Nicolas, primary, Britton, Graham J., additional, Gruber, Conor, additional, Hegde, Samarth, additional, Kim, Joel, additional, Kuksin, Maria, additional, Levantovsky, Rachel, additional, Malle, Louise, additional, Moreira, Alvaro, additional, Park, Matthew D., additional, Pia, Luisanna, additional, Risson, Emma, additional, Saffern, Miriam, additional, Salomé, Bérengère, additional, Esai Selvan, Myvizhi, additional, Spindler, Matthew P., additional, Tan, Jessica, additional, van der Heide, Verena, additional, Gregory, Jill K., additional, Alexandropoulos, Konstantina, additional, Bhardwaj, Nina, additional, Brown, Brian D., additional, Greenbaum, Benjamin, additional, Gümüş, Zeynep H., additional, Homann, Dirk, additional, Horowitz, Amir, additional, Kamphorst, Alice O., additional, Curotto de Lafaille, Maria A., additional, Mehandru, Saurabh, additional, Merad, Miriam, additional, Samstein, Robert M., additional, Agrawal, Manasi, additional, Aleynick, Mark, additional, Belabed, Meriem, additional, Brown, Matthew, additional, Casanova-Acebes, Maria, additional, Catalan, Jovani, additional, Centa, Monica, additional, Charap, Andrew, additional, Chan, Andrew, additional, Chen, Steven T., additional, Chung, Jonathan, additional, Bozkus, Cansu Cimen, additional, Cody, Evan, additional, Cossarini, Francesca, additional, Dalla, Erica, additional, Fernandez, Nicolas, additional, Grout, John, additional, Ruan, Dan Fu, additional, Hamon, Pauline, additional, Humblin, Etienne, additional, Jha, Divya, additional, Kodysh, Julia, additional, Leader, Andrew, additional, Lin, Matthew, additional, Lindblad, Katherine, additional, Lozano-Ojalvo, Daniel, additional, Lubitz, Gabrielle, additional, Magen, Assaf, additional, Mahmood, Zafar, additional, Martinez-Delgado, Gustavo, additional, Mateus-Tique, Jaime, additional, Meritt, Elliot, additional, Moon, Chang, additional, Noel, Justine, additional, O’Donnell, Tim, additional, Ota, Miyo, additional, Plitt, Tamar, additional, Pothula, Venu, additional, Redes, Jamie, additional, Reyes Torres, Ivan, additional, Roberto, Mark, additional, Sanchez-Paulete, Alfonso R., additional, Shang, Joan, additional, Schanoski, Alessandra Soares, additional, Suprun, Maria, additional, Tran, Michelle, additional, Vaninov, Natalie, additional, Wilk, C. Matthias, additional, Aguirre-Ghiso, Julio, additional, Bogunovic, Dusan, additional, Cho, Judy, additional, Faith, Jeremiah, additional, Grasset, Emilie, additional, Heeger, Peter, additional, Kenigsberg, Ephraim, additional, Krammer, Florian, additional, and Laserson, Uri, additional

Published
2020
Full Text
View/download PDF

10. The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein

Author

Ramos-Espiritu, Lavoisier, primary, Diaz, Ana, additional, Nardin, Charlee, additional, Saviola, Anthony J., additional, Shaw, Fiona, additional, Plitt, Tamar, additional, Yang, Xia, additional, Wolchok, Jedd, additional, Pirog, Edyta C., additional, Desman, Garrett, additional, Sboner, Andrea, additional, Zhang, Tuo, additional, Xiang, Jenny, additional, Merghoub, Taha, additional, Levin, Lonny R., additional, Buck, Jochen, additional, and Zippin, Jonathan H., additional

Published
2016
Full Text
View/download PDF

11. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy

Author

Khalil, Danny D.N., Murphy, Judith J.T., Wolchok, Jedd J.D., Merghoub, Taha, Budhu, Sadna, Gasmi, Billel, Zappasodi, Roberta, Hirschhorn-Cymerman, Daniel, Plitt, Tamar, De Henau, Olivier, Zamarin, Dmitriy, Holmgaard, Rikke Bæk, Khalil, Danny D.N., Murphy, Judith J.T., Wolchok, Jedd J.D., Merghoub, Taha, Budhu, Sadna, Gasmi, Billel, Zappasodi, Roberta, Hirschhorn-Cymerman, Daniel, Plitt, Tamar, De Henau, Olivier, Zamarin, Dmitriy, and Holmgaard, Rikke Bæk

Abstract

Using the immune system to control cancer has been investigated for over a century. Yet it is only over the last several years that therapeutic agents acting directly on the immune system have demonstrated improved overall survival for cancer patients in phase III clinical trials. Furthermore, it appears that some patients treated with such agents have been cured of metastatic cancer. This has led to increased interest and acceleration in the rate of progress in cancer immunotherapy. Most of the current immunotherapeutic success in cancer treatment is based on the use of immune-modulating antibodies targeting critical checkpoints (CTLA-4 and PD-1/PD-L1). Several other immune-modulating molecules targeting inhibitory or stimulatory pathways are being developed. The combined use of these medicines is the subject of intense investigation and holds important promise. Combination regimens include those that incorporate targeted therapies that act on growth signaling pathways, as well as standard chemotherapy and radiation therapy. In fact, these standard therapies have intrinsic immune-modulating properties that can support antitumor immunity. In the years ahead, adoptive T-cell therapy will also be an important part of treatment for some cancer patients. Other areas which are regaining interest are the use of oncolytic viruses that immunize patients against their own tumors and the use of vaccines against tumor antigens. Immunotherapy has demonstrated unprecedented durability in controlling multiple types of cancer and we expect its use to continue expanding rapidly., SCOPUS: ar.k, info:eu-repo/semantics/published

Published
2015

14. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19.

Author

Britton GJ, Chen-Liaw A, Cossarini F, Livanos AE, Spindler MP, Plitt T, Eggers J, Mogno I, Gonzalez-Reiche AS, Siu S, Tankelevich M, Grinspan LT, Dixon RE, Jha D, van de Guchte A, Khan Z, Martinez-Delgado G, Amanat F, Hoagland DA, tenOever BR, Dubinsky MC, Merad M, van Bakel H, Krammer F, Bongers G, Mehandru S, and Faith JJ

Abstract

We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19. We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody responses in stool from a cohort of 44 hospitalized COVID-19 patients. SARS-CoV-2 RNA was detected in stool of 41% of patients and more frequently in patients with diarrhea. Patients who survived had lower fecal viral RNA than those who died. Strains isolated from stool and nasopharynx of an individual were the same. Compared to uninfected controls, COVID-19 patients had higher fecal levels of IL-8 and lower levels of fecal IL-10. Stool IL-23 was higher in patients with more severe COVID-19 disease, and we found evidence of intestinal virus-specific IgA responses associated with more severe disease. We provide evidence for an ongoing humeral immune response to SARS-CoV-2 in the gastrointestinal tract, but little evidence of overt inflammation., Competing Interests: Declaration of interests: M.C.D is a consultant for Abbvie, Arena, BMS, Boehringer Ingelheim, Genentech, Janssen, Pfizer, Prometheus Biosciences, Takeda, Target RWE and UCB, has received research support from Janssen, Pfizer, Prometheus Biosciences and Abbvie and is co-founder of Cornerstones Health, Mitest Health, Trellus Health, M.M. is a consultant for Takeda, Genentech, Regeneron, Compugen, Myeloid Therapeutics. F.K. declares that The Icahn School of Medicine at Mount Sinai has filed patent applications regarding SARS-CoV-2 serology assays and has licensed reagents to several commercial entities. J.J.F. serves on the scientific advisor board of Vedanta Biosciences. The remaining authors declare no competing of interest.

Published
2020
Full Text
View/download PDF

15. Gastrointestinal involvement attenuates COVID-19 severity and mortality.

Author

Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, Parigi TL, Ramos I, Dunleavy K, Lee B, Dixon R, Chen ST, Martinez-Delgado G, Nagula S, Ko HM, Glicksberg BS, Nadkarni G, Pujadas E, Reidy J, Naymagon S, Grinspan A, Ahmad J, Tankelevich M, Gordon R, Sharma K, Houldsworth J, Britton GJ, Chen-Liaw A, Spindler MP, Plitt T, Wang P, Cerutti A, Faith JJ, Colombel JF, Kenigsberg E, Argmann C, Merad M, Gnjatic S, Harpaz N, Danese S, Cordon-Cardo C, Rahman A, Kumta NA, Aghemo A, Petralia F, van Bakel H, Garcia-Sastre A, and Mehandru S

Abstract

Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of coronavirus disease 2019 (COVID-19), we investigated intestinal infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its effect on disease pathogenesis. SARS-CoV-2 was detected in small intestinal enterocytes by immunofluorescence staining or electron microscopy, in 13 of 15 patients studied. High dimensional analyses of GI tissues revealed low levels of inflammation in general, including active downregulation of key inflammatory genes such as IFNG, CXCL8, CXCL2 and IL1B and reduced frequencies of proinflammatory dendritic cell subsets. To evaluate the clinical significance of these findings, examination of two large, independent cohorts of hospitalized patients in the United States and Europe revealed a significant reduction in disease severity and mortality that was independent of gender, age, and examined co-morbid illnesses. The observed mortality reduction in COVID-19 patients with GI symptoms was associated with reduced levels of key inflammatory proteins including IL-6, CXCL8, IL-17A and CCL28 in circulation but was not associated with significant differences in nasopharyngeal viral loads. These data draw attention to organ-level heterogeneity in disease pathogenesis and highlight the role of the GI tract in attenuating SARS-CoV-2-associated inflammation with related mortality benefit., One Sentence Summary: Intestinal infection with SARS-CoV-2 is associated with a mild inflammatory response and improved clinical outcomes.

Published
2020
Full Text
View/download PDF

16. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Author

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, and Merghoub T

Subjects
Animals, B7-H1 Antigen antagonists & inhibitors, Humans, Signal Transduction drug effects, T-Lymphocytes drug effects, Antineoplastic Agents therapeutic use, Immunotherapy, Neoplasms immunology, Neoplasms therapy, T-Lymphocytes immunology
Abstract

Using the immune system to control cancer has been investigated for over a century. Yet it is only over the last several years that therapeutic agents acting directly on the immune system have demonstrated improved overall survival for cancer patients in phase III clinical trials. Furthermore, it appears that some patients treated with such agents have been cured of metastatic cancer. This has led to increased interest and acceleration in the rate of progress in cancer immunotherapy. Most of the current immunotherapeutic success in cancer treatment is based on the use of immune-modulating antibodies targeting critical checkpoints (CTLA-4 and PD-1/PD-L1). Several other immune-modulating molecules targeting inhibitory or stimulatory pathways are being developed. The combined use of these medicines is the subject of intense investigation and holds important promise. Combination regimens include those that incorporate targeted therapies that act on growth signaling pathways, as well as standard chemotherapy and radiation therapy. In fact, these standard therapies have intrinsic immune-modulating properties that can support antitumor immunity. In the years ahead, adoptive T-cell therapy will also be an important part of treatment for some cancer patients. Other areas which are regaining interest are the use of oncolytic viruses that immunize patients against their own tumors and the use of vaccines against tumor antigens. Immunotherapy has demonstrated unprecedented durability in controlling multiple types of cancer and we expect its use to continue expanding rapidly., (© 2015 Elsevier Inc. All rights reserved.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results